These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1299 related articles for article (PubMed ID: 35458717)

  • 21. Psychedelic therapy in depression and substance use disorders.
    Korkmaz ND; Cikrikcili U; Akan M; Yucesan E
    Eur J Neurosci; 2024 Jul; 60(2):4063-4077. PubMed ID: 38773750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
    Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
    J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular safety of psychedelic medicine: current status and future directions.
    Wsół A
    Pharmacol Rep; 2023 Dec; 75(6):1362-1380. PubMed ID: 37874530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychedelics in the treatment of unipolar mood disorders: a systematic review.
    Rucker JJ; Jelen LA; Flynn S; Frowde KD; Young AH
    J Psychopharmacol; 2016 Dec; 30(12):1220-1229. PubMed ID: 27856684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychedelics and Personality.
    Aixalà M; Dos Santos RG; Hallak JEC; Bouso JC
    ACS Chem Neurosci; 2018 Oct; 9(10):2304-2306. PubMed ID: 29863323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Past and Future of Psychedelic Science: An Introduction to This Issue.
    Doblin RE; Christiansen M; Jerome L; Burge B
    J Psychoactive Drugs; 2019; 51(2):93-97. PubMed ID: 31132970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics.
    Hovmand OR; Poulsen ED; Arnfred S
    J Psychopharmacol; 2024 Jan; 38(1):19-32. PubMed ID: 37969069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives.
    Kaypak AC; Raz A
    Transcult Psychiatry; 2022 Oct; 59(5):665-674. PubMed ID: 36031848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.
    Wilkes R; Roberts DM; Liknaitzky P; Brett J
    Clin Toxicol (Phila); 2024 Apr; 62(4):242-247. PubMed ID: 38753585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Classical psychedelics for the treatment of depression and anxiety: A systematic review.
    Muttoni S; Ardissino M; John C
    J Affect Disord; 2019 Nov; 258():11-24. PubMed ID: 31382100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology.
    Kelly DF; Heinzerling K; Sharma A; Gowrinathan S; Sergi K; Mallari RJ
    Neurosurgery; 2023 Apr; 92(4):680-694. PubMed ID: 36512813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.
    Yao Y; Guo D; Lu TS; Liu FL; Huang SH; Diao MQ; Li SX; Zhang XJ; Kosten TR; Shi J; Bao YP; Lu L; Han Y
    Psychiatry Res; 2024 May; 335():115886. PubMed ID: 38574699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Potential Role of Psychedelic Drugs in Mental Health Care of the Future.
    Gründer G; Jungaberle H
    Pharmacopsychiatry; 2021 Jul; 54(4):191-199. PubMed ID: 33979868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The promises and perils of psychedelic pharmacology for psychiatry.
    McClure-Begley TD; Roth BL
    Nat Rev Drug Discov; 2022 Jun; 21(6):463-473. PubMed ID: 35301459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychedelic drugs-a new era in
psychiatry?
.
    Nutt D
    Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic Applications of Classic Hallucinogens.
    Bogenschutz MP; Ross S
    Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action.
    Tap SC
    Addict Biol; 2024 Apr; 29(4):e13386. PubMed ID: 38600715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.
    Madrid-Gambin F; Fabregat-Safont D; Gomez-Gomez A; Olesti E; Mason NL; Ramaekers JG; Pozo OJ
    Biomed Pharmacother; 2023 Dec; 169():115775. PubMed ID: 37944438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.